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Introduction 
Stroke is one of the leading causes of death and disability 
worldwide, and its incidence is continually growing [1]. Tissue-
type plasminogen activator (tPA) is a thrombolytic agent that 
degrades fibrin clots through activation of plasminogen to plas-
min. It is considered to be the most effective intervention for the 
emergency treatment of stroke when given within 3 h of the on-
set of stroke symptoms [2,3]. However, there are many potential 
complications of tPA treatment, including risks of hemorrhagic 
transformation, neurotoxicity, and cerebral edema [2,4]. Such 
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Background: Intravenous tissue-type plasminogen activator (tPA) is recognized as the standard treatment for ischemic 
stroke. However, its narrow therapeutic window and association with an increased risk of intracranial hemorrhage have re-
quired caution when used. In this context, several approaches are required to deal with the shortcomings of such a double-
edged drug. Anesthetics are known to protect against ischemic reperfusion injury, and their protective role in ischemic 
post-conditioning is crucial for reducing ischemia-related injury. The aim of this study was to assess the effect of isoflurane 
post-treatment on intracranial hemorrhage and cerebral infarction after tPA treatment for transient cerebral ischemia. 
Methods: Cerebral ischemia was modeled in male Sprague-Dawley rats (n = 32) by occluding the right middle cerebral 
artery for 1 h, followed by intravenous tPA administration. Rats were randomly divided into control and isoflurane post-
treatment group, and isoflurane post-treatment group was post-treated by administering 1.5% isoflurane for 1 h from the 
start of reperfusion. Twenty-four h after reperfusion, neurobehavioral changes were assessed. The extent of cerebral in-
farction and intracranial hemorrhage were also assessed by quantification of infarction volume and cerebral hemoglobin 
concentration from brain tissue, respectively. 
Results: Neurobehavioral testing showed better functional outcomes in the isoflurane post-treatment group than the 
control group. The extent of cerebral infarction and intracranial hemorrhage were both reduced in isoflurane post-treat-
ment group compared to control group. 
Conclusions: Isoflurane post-treatment may mitigate infarction volume and intracranial hemorrhage in tPA-exaggerated 
brain injury. Our findings provide an encouraging novel approach for enhancing clinical outcomes in tPA-exaggerated 
brain injury. 
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adverse effects, along with a short therapeutic time window, 
have stimulated various efforts to both increase the efficiency 
of tPA and decrease the required doses in order to extend the 
therapeutic time window [5].
Isoflurane is an inhaled anesthetic that is commonly used in 
clinical practice. Many studies have demonstrated the neuropro-
tective role of anesthetics, especially isoflurane, and their clinical 
importance in ischemia-related cerebral injury [6,7]. However, 
inquiries regarding to the effects of isoflurane on intracranial 
hemorrhage and the blood-brain barrier (BBB) integrity after 
tPA treatment are still lacking. 
This study uses a rat model to investigate the effects of isoflu-
rane on the extent of infarct volume and hemorrhagic transfor-
mation following tPA treatment for transient cerebral ischemia. 
The aim of this study was to assess the effect of isoflurane 
post-treatment on intracranial hemorrhage and cerebral infarc-
tion after tPA treatment for transient cerebral ischemia.
Materials and Methods
Animal preparation 
All animal procedures were achieved according to a protocol 
authorized by the Animal Care and Use Committee, and were 
in accordance with the National Institutes of Health guidelines 
for care and use of laboratory animals. A total of 32 adult male 
Sprague-Dawley rats weighing 280–320 g (Orientbio Inc., Seong-
nam, Korea) were used and allowed free access to food and 
water before and after experimentation. Anesthesia was induced 
with intraperitoneal injection of a mixture of 30 mg/kg zoletil 
(Virbac Lab., Carros, France) and 10 mg/kg xylazine (Bayer 
Korea Ltd., Seoul, Korea). Zoletil is a combination of tiletamine 
hypochloride and zolazepam hypochloride, which are dissocia-
tive anesthetic and benzodiazepine, respectively. Xylazine is an 
alpha-2 adrenergic agonist and acts on presynpatic and postsyn-
aptic receptors of the central and peripheral nervous systems. 
After tracheal intubation, rats were mechanically ventilated with 
50% oxygen to achieve normocapnia. Rats were placed supine 
on a heated pad, with body temperature maintained at 37 ± 0.5oC, 
according to a rectal thermometer. A polyethylene catheter (PE-50, 
Becton Dickinson, Sparks, MD, USA) was placed into the right 
femoral artery for blood pressure measurement and arterial 
blood gas samplings. 
Middle cerebral artery occlusion model and grouping 
The experimental middle cerebral artery occlusion (MCAO) 
model was generated, as previously described [8]. Under an 
operating microscope, the right common carotid, external 
carotid (EC), and internal carotid (IC) arteries were exposed. 
The EC was cut down proximal to the lingual and maxillary 
artery branches, after proper ligation and coagulation of other 
EC branches. All other branches of the EC were coagulated and 
transected. The IC and the vagus nerves were isolated carefully 
to avoid neurologic damage. A 4-0 monofilament nylon suture 
(Dermalone; United States Surgical, CT, USA) with a flame-
rounded head was inserted through the IC, using a small inci-
sion in the EC stump. The distance between the bifurcation of 
the common carotid artery and the tip of the suture was nearly 
18.5 mm in all rats, which is coherent with published descrip-
tions of the MCAO model. Cerebral blood flow was monitored 
using laser Doppler flowmetry (LDF; Omega flow, FLO-C1, 
Neuroscience, Tokyo, Japan), with a flexible probe placed in 
cortical areas supplied by the MCA (2 mm posterior and 6 mm 
lateral to the bregma). When the MCA was occluded by thread 
insertion, rats with less than a 70% reduction in cerebral blood 
flow were excluded from the experiment [9]. After 1 h of occlu-
sion, the thread was withdrawn, the skin properly sutured, and 
rats were allowed to recover. tPA (Genentech Inc., San Francisco, 
CA, USA) was administered intravenously at 10 mg/kg, or the same 
volume of solvent with a 10% bolus and 90% continuous infusion 
over 30 minutes. Rats were randomly divided into two groups: the 
control (TPA) group (n = 17) received fresh gas (FIO2 : 0.3) after re-
perfusion, and the isoflurane post-treatment (TPA + ISO) group 
(n = 15) received 1.5% isoflurane with fresh gas for 1 h from the 
start of reperfusion. All rats were sacrificed 24 h after reperfu-
sion.
Neurobehavioral assessment 
Twenty-four h after reperfusion, animals were examined 
for neurologic deficits by an investigator who was blind to the 
groups. Neurologic function was quantified using a 5-point 
score, as described previously: 0 = no deficit; 1 = failure to fully 
extend left forepaw; 2 = circling to the left; 3 = falling to the 
left; 4 = unable to walk spontaneously [10]. After the neuro-
logic assessment, the rota-rod test was performed to evaluate 
the recovery of impaired motor function after MCAO (n = 8 in 
TPA group, n = 8 in TPA + ISO group). The accelerating rota-
rod test (ENV-577; Med Associates Inc., Geordia, VT, USA) 
was performed as described by Hunter et al. [11], with a subtle 
adjustment. Exercise time was recorded as the time an animal 
remained on the accelerating rota-rod cylinder. Speed was in-
creased from 4 to 40 revolutions/minute (rpm) over 5 minutes 
(min). The trial ended when the animal either fell off the rungs, 
gripped the device, or spun around for two consecutive revolu-
tions without attempting to walk on the rungs. 
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Measurement of infarct volume and hemorrhagic 
transformation
Animals were anesthetized with a mixture of Zoletil and Xy-
lazine, and were decapitated following the completion of a neu-
rologic assessment and rota-rod test at 24 h post-reperfusion. 
Brains were quickly isolated and sectioned into 2-mm-thick se-
rial coronal slices (n = 5 per rat). Brain slices were stained with 
2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, 
St. Louis, MO, USA) in the dark at 37oC for 30 min and fixed 
with 4% paraformaldehyde (PFA; Sigma-Aldrich, St. Louis, MO, 
USA) overnight. The posterior surface of each slice was photo-
graphed and analyzed using a computer-assisted image analysis 
system (Optimas ver 6.1; Optimas, Bothell, WA, USA). The vol-
ume of the lesion was determined by the area multiplied by the 
thickness of slices. We adopted a previously described method 
to eliminate the contribution of hemorrhage to the ischemic 
lesion using the following formula: Corrected infarct volume 
= Contralateral hemisphere volume - (Ipsilateral hemisphere 
volume - Measured infarct volume) [12]. To quantify intracra-
nial hemorrhage in the ischemic hemisphere, we determined the 
hemorrhagic extent following 24 h of reperfusion. Brains were 
divided into ipsilateral and contralateral hemispheres. The cere-
bral hemorrhage volume was quantified by extracting hemoglo-
bin from the ischemic hemisphere and measuring hemoglobin 
content with a spectrophotometric assay. The TTC-stained 
ischemic hemisphere was extracted with phosphate buffer saline 
(PBS) and prepared according to a previously reported method 
[13]. After homogenizing the ischemic cerebral hemisphere in 
PBS, in a total volume of 3 ml, the homogenate was sonicated 
and centrifuged at 13,000 × g for 30 min. Then, 0.4 ml of super-
natant was mixed with 1.6 ml of Drabkin’s reagent (Sigma, St. 
Louis, MO, USA), and optical density was measured at 540 nm 
with a spectrometer 15 min later. The hemoglobin concentra-
tion was calculated using a calibrated regression line that was set 
between the optical density and the known concentration of rat 
hemoglobin.
Statistical analysis 
Data are presented as a mean ± standard error of the mean 
(SEM). Comparison between two groups was performed either 
by two-sample t-test or Mann-Whitney U test. Statistical analy-
ses were performed with PASW statistics 20 (SPSS Inc., Chicago, 
IL, USA). Differences with a P value < 0.05 were considered sta-
tistically significant. 
Results 
Effect of isoflurane post-treatment on neurobehavioral 
function following tPA-exaggerated brain injury after 
ischemia-reperfusion injury
Rats in the TPA group demonstrated a shorter duration in 
the rota-rod test (P = 0.023, Fig. 1A) and a higher neurologic 
score (P = 0.043, Fig. 1B) than rats in the TPA + ISO group, sug-
gesting that 1 h of isoflurane post-treatment reduces neurobe-
havioral functional deficit compared to rats in the TPA group. 
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Fig. 1. The effects of post-treatment with isoflurane toward neurobehavioral function. Animals in the TPA + ISO group received 1.5% isoflurane from 
the onset of reperfusion for one hour. (A) Rats in the TPA group showed a shorter duration on the rota-rod test, and (B) higher neurologic scores than 
rats in the TPA + ISO group. TPA: control group, TPA + ISO: isoflurane post-treatment group. Values shown are means ± SEM. *P value = 0.023 vs. 
TPA. †P value = 0.043 vs. TPA.
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Effect of isoflurane post-treatment on infarct volume 
and intracranial hemorrhage resulting from tPA-
exaggerated brain injury after ischemia-reperfusion 
injury 
The size of cerebral infarct and hemorrhagic transformation 
at 24 h after reperfusion were quantified to determine the effect 
of isoflurane post-treatment on tPA-exaggerated brain injury 
after cerebral ischemia-reperfusion injury. The infarct volume 
in the ipsilateral hemisphere of the TPA group was greater than 
the TPA + ISO group (P = 0.005, Fig. 2). The amount of hemor-
rhagic transformation increased significantly in the ipsilateral 
hemisphere of rats in the TPA group, as compared to rats in the 
TPA + ISO group (P < 0.01, Fig. 3). 
Mortality following tPA-exaggerated brain injury in a 
rat MCAO model
Three TPA rats and four TPA + ISO rats were excluded from 
assessment due to sustained cerebral blood flow following MCAO. 
Consistent with its beneficial effects on tPA therapy-induced 
intracranial hemorrhage in transient cerebral ischemia, isoflu-
rane post-treatment reduced mortality in our rat model. Six rats 
(42.9 %) and three rats (27.3 %) died in the TPA and TPA + ISO 
groups, respectively (Table 1); however, statistical significance 
was lacking (P = 0.677). Physiologic parameters measured prior 
to ischemia, following ischemia, and 30 min following throm-
bolysis remained within normal range for both groups. 
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Fig. 2. Post-treatment with isoflurane reduced infarct volume. Brain 
damage was estimated with TTC staining following one hour of ischemia 
and 24 h of reperfusion. Animals in the TPA + ISO group received 1.5% 
isoflurane from the onset of reperfusion for one hour. (A) Representative 
TTC stained images of brain sections from an MCAO rat. (B) 
Quantification of infarct volume (n = 5 in each group). MCAO: middle 
cerebral artery occlusion, TPA: control group, TPA + ISO: isoflurane 
post-treatment group, TTC: 2,3,5-triphenyltetrazolium chloride. Values 
shown are means ± SEM. *P value = 0.005 vs. TPA.
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Fig. 3. Post-treatment with isoflurane reduces the amount of intracranial 
hemorrhage. Animals in the TPA + ISO group received 1.5% isoflurane 
from the onset of reperfusion for one hour. TPA: control group, TPA + 
ISO: isoflurane post-treatment group. *P value < 0.01 vs. TPA.
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Discussion
Various studies have shown isoflurane as a neuroprotective 
anesthetic agent [6,7,14]. Although the neuroprotective features 
of pre- and post-treatment with isoflurane have been identified in 
various models of ischemia, the role of isoflurane in hemorrhage 
and ischemia-reperfusion is rather controversial [6,7,14-16]. In 
this study, post-treatment with isoflurane for 1 h not only de-
creased the cerebral infarct volume but also decreased hemor-
rhagic transformation in tPA-treated transient cerebral infarc-
tion in a rat model. 
To our knowledge, no prior reports have acknowledged an 
association between post-treatment with isoflurane and its ef-
fects on tPA-exaggerated brain injury in a cerebral ischemia 
model. Such results could be of great significance because they 
suggest an intervention that may prevent the undesirable hem-
orrhagic side effects of tPA treatment.
Mechanisms of action for isoflurane post-treatment include 
cerebral protective effects in response to ischemia-reperfusion, 
cell necrosis, apoptosis, and altered signaling factors [7,17]. 
Vascular endothelial growth factor (VEGF) is a major regulator 
of normal and pathologic blood vessel growth. However, VEGF 
also has the unique property of inducing vascular leak [18,19]. 
Matrix metalloproteinase-9 (MMP-9) is an enzymatic protein 
that degrade extracellular matrix, and may cause degradation of 
the BBB after cerebral ischemia-reperfusion [20]. MMP-9 can 
be activated by VEGF. Thus, MMP-9 activation may cause both 
breakdown of the BBB and intracranial hemorrhage after cere-
bral ischemia-reperfusion injury. Anesthetic pre- and post-treat-
ment in ischemia-reperfusion models results in down-regulation 
of MMP-9 and VEGF expression [16,21]. Thus, anesthetic agents 
could be used to reduce intracranial hemorrhage and the BBB dis-
ruption by lowering the levels of VEGF and MMP-9. Our study 
focused on hemorrhagic changes in the ischemia-reperfusion in-
jured brain by quantifying the hemorrhagic content in brain tis-
sues. Future, more extensive studies should focus on evaluating 
the plasma levels of MMP-9 and VEGF in ischemia-reperfusion 
models over time. This will improve our understanding of sig-
naling dynamics, instead of showing what happens at one point 
in time based on an end-point analysis of brain tissue. 
The neuroprotective effect of both pre- and post-treatment 
with inhaled anesthetics has been shown previously [7,16]. But, 
when it comes to clinical application, the role of post-treatment 
is likely of greater significance considering the nature of cerebral 
ischemia and the on-going efforts to improve neurological out-
comes in stroke victims. Thus, the cerebral-protective effect of 
isoflurane demonstrated in our tPA-treated ischemia model may 
be more clinically relevant and provide important pre-clinical 
evidence in support of clinical trials of treatment for acute 
stroke.
The benefits of tPA for the treatment of cerebral stroke have 
been clouded by its potential hemorrhagic and neurotoxic side 
effects, as well as its short therapeutic time window. Our results 
from post-treatment with isoflurane in a cerebral ischemia-re-
perfusion model show that isoflurane can ameliorate the limita-
tions of tPA. Thus, post-treatment with isoflurane may enhance 
the safety and efficacy, and lengthen the treatment window for 
tPA in stroke therapy. 
There are several limitations to our study. First, as mentioned 
previously, MMP-9 and VEGF are regarded as relevant in the 
molecular pathobiology of intracranial hemorrhage. Thus, ef-
forts to determine tissue levels for these factors will not only 
help to validate our findings, but will also allow us to understand 
the patterns of signaling. Second, efforts to assess cerebral hem-
orrhage, extravasation of red blood cells, and disruption of the 
BBB could also be adopted during experiments to obtain more 
in-depth results. Lastly, although the protective effect of isoflu-
rane post-treatment within 24 h after the reperfusion could be 
seen here, further investigations are necessary to evaluate the 
long-term clinical outcomes or even potential adverse effect of 
the treatment. 
In summary, our study showed that isoflurane post-treatment 
following tPA therapy for transient cerebral ischemia not only im-
proved neurobehavioral outcomes, but also effectively decreased 
the infarct size and amount of hemorrhagic transformation. More 
studies are needed to determine its effects on mortality.
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Table 1. Mortality after tPA Therapy for Transient Cerebral Ischemia
TPA TPA + ISO
Total 17 15
Excluded (sustained CBF)   3   4
Assessed   8   8
Death 6 (42.9%) 3 (27.3%)*
TPA: control group, TPA + ISO: isoflurane post-treatment group, CBF: 
cerebral blood flow. *P value = 0.677 vs. TPA.
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